First approved treatment for severe orthostatic hypotension

Midodrine (Bramox) provides prescribers with a licensed treatment option for patients with severe orthostatic hypotension due to autonomic dysfunction.

Midodrine was previously only available as an unlicensed special product.
Midodrine was previously only available as an unlicensed special product.

Bramox is indicated when other forms of treatment are inadequate and corrective factors have been ruled out. 

Midodrine is a prodrug of desglymidodrine, a sympathomimetic agent that stimulates peripheral α1-aderenergic receptors to cause vasoconstriction and raise peripheral arterial resistance, leading to an increase in arterial blood pressure.

Further information
View Bramox drug record 
Summary of Product Characteristics
Manufacturer: Brancaster Pharma

Bramox is available in 2.5mg and 5mg tablets. Initially patients should be prescribed 2.5mg three times daily which may be increased weekly, depending on blood pressure readings, up to a maintenance dose of 10mg three times daily. The last dose should be taken at least 4 hours before bedtime to reduce the risk of supine hypertension.

The most frequent adverse effects of midodrine are piloerection, pruritus of the scalp and dysuria.


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more